Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A case of infradiaphragmatic Hodgkin's disease (mixed pattern) associated with glomerulonephritis in the childhood is reported. The pathogenic relationship between Hodking's disease and the renal lesion is discussed.
An Esp Pediatr 1977 Dec
PMID:[Hodgkin's disease and glomerulonefritis (author's transl)]. 60 42

Combination chemotherapy, which consisted of nitrogen mustard, a vinca alkaloid, procarbazine, and prednisone, was given to 60 patients with disseminated or recurrent Hodgkin's disease. A complete remission of disease was observed in 41 patients, with a median duration of 35+ months. The longest continuing remission was 89 months, and 52% of patients who achieved a complete remission were alive five years from the start of treatment. In contrast, patients who only had a partial remission (11 patients), or failed to respond to therapy (8 patients) fared badly, with a less than 50% survival rate at one year. Response to drug therapy could not be predicted on the basis of sex, age or tumour histology, but patients who had previously received both radiotherapy and chemotherapy had a poor prognosis. Drug toxicity was substantial, but was considered acceptable in view of the clear benefit of treatment to most patients. Further improvement in the outlook of patients with advanced Hodgkin's disease is likely to result from modifications of current drug regimens, possibly combined with non-radical radiotherapy.
Med J Aust 1977 Dec 17
PMID:Hodgkin's disease: results of treatment with combination chemotherapy. 61 96

Tasmania, an island state of the Australian Commonwealth with a population of 400,000 of predominantly Anglo-Saxon heritage, has relatively centralized oncology services. A study was undertaken of all patients known in December 1971 and of all new cases diagnosed since January 1972 with all forms of leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, myeloma, and other myeloproliferative and lymphoproliferative disorders. Data were obtained with respect to lifetime residential and occupational history, schools attended, and known familial cases of any of the myeloproliferative and lymphoproliferative disorders.
Natl Cancer Inst Monogr 1977 Dec
PMID:Lymphoproliferative and myeloproliferative disease in Tasmania. 61 44

Kaposi's sarcoma was diagnosed in a 62 year old female at the last stage of an indefined malignant lymphoma. Clinically and histopathologically, some cutaneous aspects were consistent with mycosis fungoides. However, the histological examination of lymph-nodes led to the diagnosis of Hodgkin's disease, sometimes associated with features of Kaposi's sarcoma. During the past few years, the occurrence of Kaposi's sarcoma in the course of cancers, malignant lymphomas and especially during Hodgkin's disease, has been reported. It has been suggested that immunosuppressive therapy undertaken for the initial tumor could account for a viral carcinogenesis. In this respect, the vascular proliferation observed in Kaposi's sarcoma could be compared with the lymphocyte induced angiogenesis, which occurs during the experimental graft versus host reaction. Therefore, Kaposi's sarcoma could be the result of a tumoral rejection. In the case of our observation, it does not seem possible to diagnose an angio-immunoblastic lymphadenopathy; but it is of interest to note that, in this later disease, histological features of vascular neogenesis have also been reported.
Ann Dermatol Venereol 1977 Dec
PMID:[Kaposi's sarcoma and malignant lymphoma. Discussion of this association (author's transl)]. 61 48

Retrospective analysis of 232 cases of Hodgkin's disease (HD) treated at the University of Manitoba from Jan. 1, 1965, to Dec 31, 1973, and followed up to 44.3 months disclosed five cases of secondary malignant neoplasms. Two cases of acute leukemia were discovered compared with an expected value of 0.05 in our community. All neoplasms developed in the mixed cellularity group, representing only 28% of the HD cases. Combinations of radiotherapy and chemotherapy may have increased the incidence of leukemia, but its frequency does not appear high enough to abandon combined modality treatment.
 ...
PMID:Secondary malignant neoplasms in patients with Hodgkin's disease. 65 Aug 29

In 1971 participants in the Ann Arbor Conference on Hodgkin's disease thought that pruritus had no independent prognostic importance. We reviewed our series of patients with Hodgkin's disease and found six patients in whom severe itching was a major clinical problem. When compared with similarly treated patients without pruritus, these patients appeared to have more-aggressive disease. Severe itching, alone or with B symptoms, needs further study, since it may presage a poor prognosis.
JAMA 1978 Dec 15
PMID:Prognostic importance of pruritus in Hodgkin's disease. 71 7

Although staging laparotomy changes the stage of one third of patients with Hodgkin's disease, this change in stage does not establish that routine staging laparotomy is of clinical value. The value of laparotomy depends on the results of clinical decisions which are based on the information provided by laparotomy. Increased accuracy in staging may improve clinical results by eliminating undertreatment, with an increased risk of relapse, or overtreatment with an increased risk of morbidity--including second malignancies. In some clinical settings information provided by laparotomy may be clinically irrelevant. Since clinical studies have not established the optimal therapy for every stage of Hodgkin's disease, rigid guidelines for performing staging laporotomies cannot be established. However, staging laparotomy should be done only after consideration of how the information provided by laparotomy will affect clinical decisions. Recent evidence that the extent of abdominal nodal involvement has major prognostic implications may play a role in this decision-making process.
South Med J 1978 Dec
PMID:Staging laparotomy in Hodgkin's disease: a critical appraisal of its value. 72 35

The NBT-test was performed in 54 patients with Hodgkin and non-Hodgkin lymphoma showing no bacterial infection exept for one case. 18 patients presented, at onset of the disease, a number of neutrophilic NBT-reducing granulocytes at pathological levels (greater than 12%). In order to evaluate the influence of cytostatic drugs on NBT-test serial blood samples were taken during polychemotherapy in 17 patients with lymphoma. In our experience, cytostatics (COPP) do not necessarily lessen NBT-reducing activity of granulocytes. The results suggest that the NBT in malignant lymphomas could not be used as an indication of bacterial infection.
Blut 1978 Dec 15
PMID:Evaluation of non-stimulated nitroblue-tetrazolium test in patients with malignant lymphomas. 72 24

Studies with interference contrast microscopy reveal that platelets undergo a typical shape change within 30--60' after venepuncture, i.e. swelling, formation of large tentacles, tiny protrusions and vesicles at the platelet surface. This "shape change" can be observed in citrated blood and PRP, heparinized blood and EDTA-blood as well. It is enhanced by low incubation temperatures (4 degrees C, 10 degrees C) and delayed at 37 degrees C as compared with room temperature. An increased number of primarily shape changed platelets is found if platelets are strongly mechanically irritated at blood sampling. The shape change is partly reversible in vitro, it is completely or almost completely reversible in vivo. Some antiaggregating agents inhibit the in vitro shape change at varying degrees (Bencyclan, SH 869 greater than ASA greater than D-Propranolol). The shape change is partly inhibited after oral or i.v. administration of ASA. A typical transformation of platelets into "spheric" forms can be observed following the addition of Bencyclan, SH 869 and D-Propranolol to PRP in vitro. The spontaneous "primary shape change" which occurs in PRP or blood after blood sampling is probably different from the secondary ADP-induced shape change. The primary shape change may influence the results of different platelet function and aggregating tests. The shape change kinetics of "healthy" subjects and patients with Hodgkin's disease differ significantly. The described method may gain more clinical interest in the future.
Blut 1978 Dec 15
PMID:[Primary shape change of platelets in vitro (author's transl)]. 72 25

Thyroid function and scans were evaluated in fifty disease-free patients 2 to 16 years after receiving neck irradiation for the treatment of Hodgkin's disease. Twenty-five of 50 patients had abnormal thyroid studies: eight were hypothyroid, two were hypothyroid and had abnormal scans, and fifteen had abnormal scans. Of the 15 patients with abnormal scans, one had an isolated elevation of TSH (thyroid stimulating hormone) and one developed exophthalmos. These data, obtained within a relatively short follow-up period, indicate that morphologic and functional abnormalities of the thyroid gland are not uncommon in patients who have received irradiation to the thyroid gland in the course of treatment for Hodgkin's disease. There is need for continuous reevaluation of the thyroid status in such patients.
Cancer 1978 Dec
PMID:Thyroid abnormalities following neck irradiation for Hodgkin's disease. 72 60


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>